The Australian: Island Pharma gets much-needed cash for trial  
    Grant to directly support ISLA-101 Phase 2a trial  
    Island Pharmaceuticals CEO: ISLA-101 Shows Promise in Dengue Fever Fight, Phase 2a next  
    Island CEO David Foster speaks with Stockhead on drug repurposing  
    Island Pharmaceuticals advances dengue fever treatment with promising ISLA-101 study results  
    Island Pharmaceuticals to raise $1.95 million for ISLA-101 development  
    Island Pharmaceuticals targets $1.95 million in new capital raise  
    Island Pharmaceuticals confirms all doses in ISLA-101 study safe and well tolerated by volunteers  
    Island Pharmaceuticals advances critical study of antiviral drug ISLA-101 against dengue  
    Island Pharmaceuticals advances with ISLA-101 study for Dengue with third cohort dosing  
    Island Pharmaceuticals repurposing established drug to address global threat of mosquito-borne disease  
    Island Pharmaceuticals kicks off dosing for third cohort of ISLA-101 single ascending dose study for dengue treatment  
    Island Pharmaceuticals secures loan facility with Radium Capital based on forecast R&D tax incentive claim  
    Island Pharmaceuticals doses second cohort of subjects in ISLA-101 Single Ascending Dose study  
    Island MD David Foster speaks to Bulls N' Bears about ISLA-101 and more  
    Island Pharmaceuticals appoints new joint company secretary  
    Island Pharmaceuticals kicks off "critical" study in Dengue fight  
    Island Pharma one step closer to ISLA-101 dosing  
    Island Pharmaceuticals gets ready to tackle mosquito-borne diseases as warmer climate accelerates spread  
    Island Pharmaceuticals initiates screening for ISLA-101 study to combat mosquito-borne disease  
    Island Pharmaceuticals nets over $300,000 in R&D tax refund  
    Island Pharmaceuticals gains ISLA-101 study ethics approval for dengue fever  
    Island Pharma welcomes green light for ISLA-101 clinical study  
    Island Pharmaceuticals granted Australian patent for ISLA-101  
    Island Pharmaceuticals CEO and Managing Director Dr David Foster on ausbiz  
    Island Pharma gearing up to start ISLA-101 trial for dengue fever  
    Island Pharmaceuticals readies for ISLA-101 trial for dengue fever  
    Island Pharmaceuticals secures key US patent for dengue fever treatment  
    $US1.3m grant for dengue fever study  
    Island Pharmaceuticals secures US grant funding to support clinical development of dengue fever candidate  
    Island Pharmaceuticals sees tremendous opportunity for mosquito-borne virus program  
    Island Pharmaceuticals receives FDA green light for dengue virus ISLA-101 clinical program  
    Island Pharmaceuticals completes major body of work as it responds to FDA's ISLA-101 requests  
    Connecting the world to powerful outcomes: Island Pharmaceuticals  
    Connecting the world to powerful outcomes: David Foster  
    Island Pharmaceuticals "appreciates" detailed FDA feedback on IND application  
    Island CEO Dr David Foster discusses FDA feedback on IND for ISLA-101 clinical study  
    Island Pharmaceuticals receives FDA feedback on IND for Phase 2a clinical trial of dengue vaccine  
    Island Pharmaceuticals could see a re-rating on positive Phase 2a results in H2CY23: MST Access  
    Island Pharmaceuticals on track to begin ISLA-101 Phase 2a clinical trial in early 2023: MST Access Research  
    Island Pharmaceuticals submits IND application for Phase 2a clinical trial in dengue fever  
    Island Pharmaceuticals targets Mosquito-borne viruses with antiviral pipeline  
    Island gets the nod to start Phase 2a trial  
    Island Pharmaceuticals receives Institutional Review Board approval to begin ISLA-101 Phase 2a clinical trial  
    Are children in Singapore facing a 'tripledemic' threat of influenza, Covid-19 and RSV?  
    More than 30,000 dengue cases reported in 2022  
    ShareCafe Hidden Gems webinar presentation  
    Stockhead Health & Biotech Investment Guide  
    Dengue cases continue to rise – DOH  
    MST Access initiates research coverage on Island Pharmaceuticals  

Island is pleased to share the news that MST Access analyst, Rosemary Cummins, has initiated research coverage on Island Pharmaceuticals (ASX: ILA.)

In her report, entitled, “Primed for Success”, Ms Cummins provides a summary of Island’s approach to repurposing drugs, like ISLA-101, for viral illnesses.

MST has noted a 12 month forward valuation for Island of $112m from the date of release, subject to the Company achieving its aims over this period.

To view a copy of the report, please click here.

    Miami under alert as first confirmed case of dengue fever is reported  
    ShareCafe February 2022, Investor Presentation  
    Video - Dengue: A Viral Pandemic  
    The conversation: After a horrific COVID wave, India’s health system is now overwhelmed by a different virus  
    Scroll in: Why is India seeing a massive dengue outbreak this year?  
    Australian Geographic: Upcoming mosquito season may be the worst yet. Here’s how to prepare yourself  
    ABC News: Sunshine Coast leads Queensland for Ross River virus cases  
    Al Jazeera: Infographic: What is dengue and how does it spread?  
    Outbreak News: Colombia issues dengue fever alert  
    The Market Herald: Island Pharmaceuticals signs contract for dengue fever trial  
    Pandemic Economic Recovery Could Worsen Climate Change Health Impacts  
    Island attending at Pharma Meeting Brazil & Latam 2021  
    Pitt Street Research: Video interview David Foster CEO  
    The Market Herald: Island Pharmaceuticals (ASX:ILA) granted Australian patent for Dengue treatment  
    Financial Express: Over 200 dengue cases daily since August 1  
    National geographic: Wild U.S. deer found with coronavirus antibodies  
    Biotech Daily: Island says Cerrx will supply synthesized starting material  
    Cook Island NEWS: Two new dengue cases  
    ABC NEWS: India's Kerala state issues state-wide alert after Zika virus cases detected  
    The Hill: US faces more risk of malaria, dengue due to climate change: study  
    Onlinelibrary.wiley: Re-defining the dengue-receptive area of Queensland after the 2019 dengue outbreak in Rockhampton  
    Biotech Daily: Dr Boreham's Crucible - Island Pharmaceuticals  
    Cook Islands dengue outbreak now 162 cases  
    Ausbiz: CEO Dr David Foster talks about Island's successful IPO  
    OnMarket Video: Introduction to Island Pharmaceuticals | ASX: ILA  
    Dengue fever outbreak in Cook Islands  
    Key patent granted for Isla101 in Brazil  
    Dengue In The Time Of COVID: Keys Fighting On Two Viral Fronts  
    Dengue and COVID-19: Chaotic Potential? -  
    Dengue virus tests may sometimes return ‘positive’ for coronavirus, says study